Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective

Jan Zeidler (), Thomas Mittendorf (), Rüdiger Müller () and Johannes von Kempis ()

Health Economics Review, 2012, vol. 2, issue 1, 1-8

Abstract: Marked differences in costs between subcutaneous and intravenous therapies were observed. Among the three groups of patients defined by TNF inhibitor treatment, costs for the infliximab group were highest during the year after the index event. Copyright Zeidler et al.; licensee Springer. 2012

Keywords: Inflammatory rheumatic diseases; Claims data; Cost analysis; Dosing patterns; Switzerland; Tumor necrosis factor inhibitor (search for similar items in EconPapers)
Date: 2012
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1186/2191-1991-2-20 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:2:y:2012:i:1:p:1-8:10.1186/2191-1991-2-20

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/2191-1991-2-20

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().